Downtrend on the daily chart: below its 50- and 200-day averages · 50-day below the 200-day · SuperTrend down since Mar 24 · below the Ichimoku cloud · RSI 37 · MACD below its signal · 2% above its 52-week low
None of the 29 investors followed here reported a position in OGEN in their latest filing.
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a OGEN trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 7.7 | 0.0 | -33.3 | 5.4 | 3.4 | -4.9 | -13.8 | 2.0 | -3.9 | -8.8 | −42.7% | ||
| 2025 | -16.2 | -6.5 | -27.6 | -9.5 | -36.8 | 6.1 | -67.0 | -18.3 | 27.2 | -6.1 | -29.3 | -10.3 | −93.0% |
| 2024 | -59.1 | -37.8 | 0.7 | -28.5 | 96.1 | -48.5 | 0.0 | 22.1 | -70.1 | -18.4 | 3.2 | 15.6 | −93.4% |
| 2023 | 0.0 | -30.3 | -28.5 | -14.9 | 6.4 | 11.1 | 17.8 | -7.7 | -17.5 | 22.6 | -1.6 | 57.3 | −14.7% |
| 2022 | -6.7 | -11.9 | -8.1 | -2.9 | 0.0 | 6.1 | 2.9 | -13.9 | -25.8 | -4.3 | -9.1 | -45.0 | −75.6% |
| 2021 | 104.4 | 10.9 | -10.8 | -12.1 | -13.8 | 2.9 | 12.7 | -10.0 | -12.5 | 1.6 | -9.4 | -22.4 | 0.0% |
| 2020 | -15.4 | 70.5 | -22.7 | -25.9 | 30.2 | 23.2 | 75.4 | -39.7 | -21.9 | -17.5 | -8.5 | 4.7 | −13.5% |
| 2019 | 8.1 | -5.4 | -33.0 | -10.2 | -11.3 | 4.3 | -8.2 | -11.1 | 35.0 | -18.5 | 40.9 | -16.1 | −39.5% |
| 2018 | -5.2 | -20.6 | 0.6 | -25.3 | 15.4 | -8.0 | -58.0 | -25.9 | 167.4 | -13.0 | 35.0 | -36.3 | −62.6% |
| 2017 | 29.6 | -11.4 | -29.0 | -2.3 | 11.6 | -22.9 | 5.4 | -17.9 | 31.3 | -19.0 | 17.6 | -42.5 | −57.4% |
| 2016 | -31.3 | 2.9 | -15.1 | -4.4 | -33.7 | -10.5 | 41.2 | -4.2 | -33.3 | -8.7 | 52.4 | -15.6 | −64.0% |
| 2015 | -11.2 | 45.6 | -11.3 | -15.7 | -11.6 | 80.3 | 91.2 | -13.7 | -27.4 | -18.9 | 12.8 | 0.0 | +68.5% |
| 2014 | 33.1 | 0.0 | -23.3 | -30.3 | 2.5 | -4.9 | -9.7 | -5.7 | -24.7 | -16.0 | -11.4 | -4.3 | −68.3% |
| 2013 | 21.2 | 8.1 | -3.2 | 1.5 | -16.5 | 9.2 | 1.6 | 0.0 | -4.8 | -12.7 | 13.7 | -5.7 | +6.4% |
| 2012 | 18.8 | 74.2 | -40.2 | 28.0 | -17.5 | 85.6 | 6.1 | -3.8 | -12.0 | -18.2 | 15.0 | 27.5 | +161.4% |
| 2011 | 60.0 | -27.1 | -5.7 | 27.3 | 30.7 | -39.9 | 0.0 | -28.8 | -34.0 | 16.1 | -5.6 | -40.6 | −66.3% |
| 2010 | 100.0 | -11.7 | 7.5 | 22.8 | -24.3 | -34.0 | 8.6 | -10.5 | -2.9 | -39.4 | 0.0 | -25.0 | −50.0% |
| 2009 | 0.0 | 24.0 | -9.7 | -75.0 | 42.9 | 150.0 | 16.0 | -3.4 | -7.1 | 3.8 | 3.7 | 7.1 | +20.0% |
| 2008 | 14.6 | 21.3 | -28.1 | 80.5 | -33.8 | 12.2 | -9.1 | 14.0 | 49.1 | -38.8 | -23.1 | -37.5 | −39.0% |
| 2007 | -22.7 | 22.4 | -2.9 | -19.8 | -60.5 | 15.6 | 40.5 | -17.3 | 4.7 | 31.1 | -16.9 | -16.3 | −62.7% |
| Date | Insider | Transaction | Shares | Value |
|---|---|---|---|---|
| Dec 11, 2025 | Telling Frederick WDirector | Sale at price 0.94 per share. | 210 | $198 |
| Dec 11, 2025 | Telling Frederick WDirector | Sale at price 0.94 per share. | 210 | $198 |
| Jun 17, 2025 | Odyssey Health, IncBeneficial Owner of more than 10% of a Class of Security | Sale at price 4.26 - 4.46 per share. | 7K | $30.41K |
| Jun 15, 2025 | Odyssey Health, IncBeneficial Owner of more than 10% of a Class of Security | Sale at price 4.27 - 4.45 per share. | 10K | $43.60K |
| Dec 10, 2024 | Koski Robert CDirector | — | 5K | — |
| Dec 5, 2024 | Dunton Alan WilliamDirector | Sale at price 0.36 per share. | 66 | $24 |
| Dec 5, 2024 | Telling Frederick WDirector | Sale at price 0.36 per share. | 3.6K | $1.29K |
No analyst coverage for this instrument.
Oragenics, Inc., a development-stage company, engages in the research and development of nasal delivery pharmaceutical therapies neurological conditions and infectious diseases in the United States. Its lead product is ONP-002, a fully synthetic, non-naturally occurring neurosteroid, which is lipophilic and can cross the blood-brain barrier to reduce swelling, oxidative stress, and inflammation while restoring proper blood flow through gene amplification for the treatment of mild traumatic brain injury. The company was formerly known as Oragen, Inc. Oragenics, Inc. was incorporated in 1996 and is headquartered in Lakewood Ranch, Florida.